Search results for "Protein"

showing 10 items of 21431 documents

Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk

2015

Clinical guidelines should be based on the best available evidence and are of great importance for patient care and disease prevention. In this respect, the 2013 American College of Cardiology/American Heart Association report is highly appreciated and well-recognized. The report included critical questions concerning hypercholesterolaemia, but its translation into a clinical guideline initiated intense debate worldwide because of the recommendation to switch from a treat-to-target approach for low-density-lipoprotein-cholesterol to a statin dose-based strategy.

medicine.medical_specialtyConsensusStatinEpidemiologymedicine.drug_classHypercholesterolemia610 Medicine & healthComorbidity030204 cardiovascular system & hematologyRisk Assessment2705 Cardiology and Cardiovascular MedicinePatient care03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk Factors540 ChemistrymedicineHumans030212 general & internal medicineIntensive care medicine10038 Institute of Clinical Chemistrybusiness.industryCholesterolTreat to targetCholesterol LDLGuidelineStatin treatmentTreatment OutcomechemistryCardiovascular DiseasesPractice Guidelines as TopicPhysical therapyLDL Cholesterol Lipoproteinslipids (amino acids peptides and proteins)Disease preventionHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessBiomarkers2713 EpidemiologyEuropean Journal of Preventive Cardiology
researchProduct

Acquired haemophilia in cancer: A systematic and critical literature review

2017

Aim There is a paucity of data on the clinical presentation and management of cancer patients with acquired haemophilia (AH), we here report a systematic literature review on acquired haemophilia in the context of cancer. Methods Treatment outcomes of AH were defined as complete response (CR), partial response (PR) or no response (NR), based on inhibitor eradication, coagulation factor VIII levels and bleeding control. Reported deaths were either related to cancer or bleeding. Results Overall, 105 cases were collected and analyzed according to classification of cancer and efficacy of treatments for inhibitor and malignancy. The mean age was 68 years for both males (range 37-86 years) and fe…

medicine.medical_specialtyContext (language use)Antineoplastic AgentsFactor VIIa030204 cardiovascular system & hematologyMalignancyHemophilia AGastroenterology03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesInternal medicineNeoplasmsAcquired haemophiliamedicineHumanscancerhaematological malignancyGenetics (clinical)Blood Coagulation Factor Inhibitorstreatmentbusiness.industryIncidence (epidemiology)AutoantibodyCancerHematologyGeneral Medicinemedicine.diseasebleedingBlood Coagulation FactorsRecombinant ProteinsSurgeryinhibitordiagnosiSystematic reviewTreatment Outcome030220 oncology & carcinogenesisHematologic Neoplasmsacquired haemophilabusinessHaematological malignancy
researchProduct

Analysis of Rabbit Vascular Responses to DBI, an Ingol Derivative Isolated from Euphorbia canariensis

1997

Abstract We have analysed the effects of 7,12-O-diacetyl-8-O-benzoil-2,3-diepiingol (DBI), an ingol derivative isolated from E. canariensis, on isometric tension developed by isolated rabbit basilar and carotid arteries. Concentration-response curves to DBI (10−8 - 3 × 10−5 m) were obtained cumulatively in both arteries at resting tension and active tone (KC1, 50 mm). At resting tension, DBI induced a concentration-dependent contraction, which was not inhibited in Ca2+-free medium. H7 (1-(5-isoquinoline sulphonyl)-2-methylpiperazine dichloride) (10−4 m) inhibited the DBI-induced contraction both in basilar and in carotid arteries. Calmidazolium (10−4 m) inhibited the maximum contraction of …

medicine.medical_specialtyContraction (grammar)LatexCarotid Artery CommonMuscle RelaxationPharmaceutical ScienceProstacyclinNitric OxideNitroarginineMuscle Smooth VascularEuphorbia canariensisCalmodulin1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineInternal medicinemedicine.arterymedicineBasilar arteryAnimalsEnzyme InhibitorsProtein Kinase CPharmacologyPlants MedicinalLagomorphabiologyPlant Extractsbiology.organism_classificationEpoprostenolEndocrinologymedicine.anatomical_structureBasilar ArteryCirculatory systemcardiovascular systemCalciumRabbitsDiterpenesMuscle Contractionmedicine.drugBlood vesselArteryJournal of Pharmacy and Pharmacology
researchProduct

Effects of inhibitors of cGMP-dependent protein kinase in atrial heart and aortic smooth muscle from rats

1995

Several activators of cGMP-dependent protein kinase (protein kinase G) such as 8-Br-cGMP reduced force of contraction in rat left atria. Inhibitors of protein kinase G antagonized the negative inotropic effect of 8-Br-cGMP but not of acetylcholine in atria. However, the acetylcholine-induced relaxation in aortic rings was significantly inhibited by protein kinase G inhibition. It is concluded that the reduction by 8-Br-cGMP of force of contraction in atria is related to activation of protein kinase G. In response to acetylcholine, activation of protein kinase G is probably a major step in smooth muscle relaxation but is not involved in the reduction of force of contraction in atria.

medicine.medical_specialtyContraction (grammar)Muscle RelaxationAorta ThoracicIn Vitro TechniquesMuscle Smooth VascularIsometric ContractionInternal medicineCyclic GMP-Dependent Protein KinasesmedicineAnimalsHeart AtriaProtein kinase ACyclic GMPRho-associated protein kinasePharmacologybiologyHeartMyocardial ContractionAcetylcholineRatsEnzyme ActivationEndocrinologyEnzyme inhibitorSecond messenger systemcardiovascular systembiology.proteinmedicine.symptomcGMP-dependent protein kinaseAcetylcholineMuscle Contractionmedicine.drugMuscle contractionEuropean Journal of Pharmacology
researchProduct

Abnormal Haemostasis and Blood Viscosity in Malignant Hypertension

1984

SummaryWe have previously shown abnormalities of haemostasis suggestive of intravascular coagulation in patients with malignant hypertension, a condition associated with retinopathy and renal fibrin deposition. To determine whether such abnormalities are specific to malignant hypertension, we have measured several haemostatic and haemorheological variables in 18 patients with malignant hypertension (Group 1), 18 matched healthy controls (Group 2), and 18 patients with non-malignant hypertension (Group 3) matched for renal pathology, blood pressure and serum creatinine with Group 1. Both Groups 1 and 3 had increased mean levels of fibrinogen, factor VIIIc, beta-thrombo- globulin, plasma visc…

medicine.medical_specialtyCreatininebiologybusiness.industryAntithrombinBlood viscosityHematologyFibrinogenGastroenterologyFibrinchemistry.chemical_compoundBlood pressurechemistryRenal pathologyInternal medicineHemostasismedicinebiology.proteinbusinessmedicine.drugThrombosis and Haemostasis
researchProduct

ATG16L1 contribution to Crohnʼs disease risk in Sicily

2011

medicine.medical_specialtyCrohn's diseaseSettore MED/09 - Medicina InternaPolymorphism Geneticbusiness.industryGastroenterologyAutophagy-Related Proteinsmedicine.diseaseGastroenterologyCrohn DiseaseRisk FactorsInternal medicinemedicineHumansImmunology and AllergyCarrier ProteinsbusinessCrohn's disease.genetics.ATG16L1SicilyATG16L1Inflammatory Bowel Diseases
researchProduct

Size and subclasses of low-density lipoproteins in patients with obstructive sleep apnea.

2012

Patients with obstructive sleep apnea (OSA) have proatherogenic dyslipidemia. We analyzed predictors of low-density lipoproteins' (LDLs) size in patients with OSA. In a cross-sectional study including 58 participants with OSA (30 without the metabolic syndrome [MetS] and 28 with MetS), we evaluated the size of LDL by gradient gel electrophoresis. Compared with patients without the MetS, those with MetS showed lower LDL size ( P = .007), due to a reduction in large LDL-I particles ( P = .002) and an increase in small, dense LDL-IIIA ( P = .048) and LDL-IIIB ( P = .037). The size of LDL correlated inversely with age ( r = −.268, P = .042) and serum triglycerides ( r = −.364, P = .005), and p…

medicine.medical_specialtyCross-sectional studyPolysomnography10265 Clinic for Endocrinology and Diabetology610 Medicine & healthPolysomnography2705 Cardiology and Cardiovascular MedicineInternal medicinemedicineLow densityobstructive sleep apnea metabolic syndrome low-density lipoprotein size small dense low-density lipoprotein atherosclerosisHumansIn patientDyslipidemiasMetabolic SyndromeSleep Apnea Obstructivemedicine.diagnostic_testbusiness.industrySleep apneamedicine.diseaseLipoproteins LDLObstructive sleep apneaCross-Sectional StudiesEndocrinologyLinear Modelslipids (amino acids peptides and proteins)Metabolic syndromeCardiology and Cardiovascular MedicinebusinessDyslipidemia
researchProduct

A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor i…

1994

Thirty patients with measurable metastatic breast carcinoma were treated with a combination of cyclophosphamide 600 mg/m2 on day 1, levofolinic acid 100 mg/m2 plus 5-fluorouracil 375 mg/m2 on days 1-3, and epidoxorubicin (EDXR) in three refracted doses on days 1-3 with G-CSF rescue for 10 days. In the phase I part of the study, groups of 3 patients received EDXR 20, 25, 30, 35, and 40 mg/m2/day until the dose limiting toxicity (DLT) was reached. At the dose of 40mg/m2/day prolonged grade 4 leukopenia, severe proctitis, and grade 3 diarrhea represented the DLT. All subsequent partients were treated at the maximal tolerated dose of EDXR (35 mg/m2/day). In the group of 18 patients treated at 3…

medicine.medical_specialtyCyclophosphamideSettore MED/06 - Oncologia Medicamedicine.medical_treatmentLeucovorinBreast NeoplasmsGastroenterologyDrug Administration ScheduleInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineCarcinomaHumansRadiology Nuclear Medicine and imagingCyclophosphamideEpirubicinChemotherapyLeukopeniabusiness.industryCarcinomaHematologyGeneral MedicineLeukopeniaMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryGranulocyte colony-stimulating factorSettore MED/18 - Chirurgia GeneraleRegimenTreatment OutcomeOncologyFluorouracilToxicityFemaleFluorouracilmedicine.symptombusinessmedicine.drugActa oncologica (Stockholm, Sweden)
researchProduct

Renal Lipotoxicity-Associated Inflammation and Insulin Resistance Affects Actin Cytoskeleton Organization in Podocytes

2015

In the last few decades a change in lifestyle has led to an alarming increase in the prevalence of obesity and obesity-associated complications. Obese patients are at increased risk of developing hypertension, heart disease, insulin resistance (IR), dyslipidemia, type 2 diabetes and renal disease. The excess calories are stored as triglycerides in adipose tissue, but also may accumulate ectopically in other organs, including the kidney, which contributes to the damage through a toxic process named lipotoxicity. Recently, the evidence suggests that renal lipid accumulation leads to glomerular damage and, more specifically, produces dysfunction in podocytes, key cells that compose and maintai…

medicine.medical_specialtyCytochalasin DPalmitic Acidlcsh:MedicineApoptosisKidneyActin cytoskeleton organizationCell LinePodocyteNephrinMiceInsulin resistanceInternal medicineLipid dropletmedicineAnimalslcsh:ScienceInflammationMultidisciplinarybiologyPodocyteslcsh:REndoplasmic Reticulum StressLipid Metabolismmedicine.diseaseActin cytoskeletonActin CytoskeletonOxidative StressEndocrinologymedicine.anatomical_structureLipotoxicitybiology.proteinSlit diaphragmlcsh:QInsulin ResistanceResearch ArticlePLOS ONE
researchProduct

18-hydroxylation in the Y-1 adrenal cell line: response to ACTH and to culture conditions.

1992

The 18-hydroxylation of deoxycorticosterone in the Y-1 adrenal cell line was studied under various incubation and cell culture conditions and compared to 11 beta-hydroxylation. Repeated incubation of the substrate increased both 18- and 11 beta-hydroxylation in the Y-1 cells. Furthermore, both 18- and 11 beta-hydroxylation were increased with increased serum concentration and prolonged incubation time. While the increase in 11 beta-hydroxylation seemed to be independent of the type of serum, 18-hydroxylation was much more important in cells cultured in fetal or newborn calf serum supplemented medium than in those cultured in horse serum supplemented medium. As expected, ACTH treatment incre…

medicine.medical_specialtyCytochromeEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryHydroxylationBiochemistryHydroxylationchemistry.chemical_compoundMiceEndocrinologyAdrenocorticotropic HormoneCytochrome P-450 Enzyme SystemInternal medicineAdrenal GlandsmedicineAnimalsCytochrome P-450 CYP11B2DesoxycorticosteroneMolecular BiologyIncubationCells CulturedFetusbiologyDose-Response Relationship DrugSubstrate (chemistry)Cell BiologyFetal BloodIn vitroCulture MediaSteroid hormoneEndocrinologyBloodchemistryCell cultureSteroid Hydroxylasesbiology.proteinMolecular MedicineSteroid 11-beta-HydroxylaseThe Journal of steroid biochemistry and molecular biology
researchProduct